REFERENCES
- Cotzias, G. G, Van Woert, M. H. and Schiffer, L. M.: Aromatic amino acids and modification of parkinsonism. New Eng J Med 276: 374, 1967.
- Cotzias, G. G, Papavasiliou, P. S. and Gellene, R.: Modification of parkinsonism—chronic treatment with L-DOPA. New Eng J Med 280: 337, 1969.
- Calne, D. B., Stern, G. M., Laurence, D. R., Sharkey, J. and Armitage, P.: L-DOPA in postencephalitic parkinsonism. Lancet 1: 744, 1969.
- Godwin-Austen, R. B., Tomlinson, E. B., Frears, C. C. and KOK, H. W. L.: Efferts of L-DOPA in Parkinson's disease. Lancet 2: 165, 1969
- Yahr, M. D., Duvoisin, R. G, Schear, M. J., Barrett, R. E. and Hoehn, M. M.: Treatment of parkinsonism with levodopa. Arch Neurol 21: 343, 1969
- Calne, D. B., Spiers, A. S. D., Stern, G. M., Laurence, D. R. and Armitage, P.: L-DOPA in idiopathic parkinsonism. Lancet 2: 973, 1969.
- Barbeau, A.: L-DOPA therapy in Parkinson's disease. Canad Med Ass J 101: 791, 1969.
- McDowell, F., Lee, J. E., Swift, T., Sweet, R. D., Ogsbury, J. S. and Kessler, J. T.: Treatment of Parkinson's syndrome with L-dihydroxyphenylalanine (levodopa). Ann Intern Med 72: 29, 1970.
- Sano, I., Gamo, T., Kakimoto, Y., Taniguchi, K., Takesada, M. and Nishinuma, K.: Distribution of catechol compounds in human brain. Biochem Biophys Acta 32: 586, 1959.
- Ehringer, N. and Hornykiewicz, O.: Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38: 1236, 1960.
- Hornykibwicz, O.: Die topische Lokalisation und das Verhalten von Noradrenalin und Dopamin (3- Hydroxytyramin) in der Substantia nigra des normalen und parkinsonkranken Menschen. Wien Klin Wschr 75: 309, 1963.
- Greenfield, J. G.: In Critchley, M. (Editor): James Parkinson 1755–1824. A Bicentenary Volume of Papers Dealing With Parkinson's Disease. New York, The Macmillan Company, 1955, p 219
- Gey, K. F. and Pletscher, A.: Distribution and metabolism of DL-3,4-dihydroxy (2-MC) phenylalanine in rat tissues. Biochem J 92: 300, 1964.
- Hornykiewicz, O.: Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18: 925, 1966.
- Carlsson, A., Lindqvist, M., Magnusson, T. and Waldeck, B.: On the presence of 3-hydroxytyramine in brain. Science 127: 471, 1958.
- Carlsson, A. and Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol 20: 140, 1963.
- Duvoisin, R. G.: Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17: 124, 1967.
- Coyle, J. T. and Snyder, S. H.: Antiparkinsonian drugs: Inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 166: 899, 1969.
- Birkmayer, W. and Hornykiewicz, O.: Der L-3,4-dioxyphenylalanin (=DOPA)-Effekt bei der Par- kinson-Akinese. Wien Klin Wschr 73: 787, 1961.
- Martin, W. E.: Unpublished data.
- Tissot, R., Gaillard, J. M., Guggisberg, M., Gauthier, G. and De Ajuriaguerra, J.: Therapeutique du syndrome de Parkinson par la L-DOPA “per os” associee a un inhibiteur de la decarboxylase (Ro IV 46.02). Presse Med 77: 619, 1969-